Partial
Partially Aligned
Patient Risk:
Medium
Summary
Most core pharmacology and interaction directions (notably grapefruit juice and several interacting drug classes) are consistent with the label, but multiple claims are unsupported, overstated, or mischaracterized relative to what the provided label text explicitly supports (e.g., warfarin/digoxin/arrhythmia, rifampin effects direction, and several specific adverse outcomes).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower low-density lipoprotein (LDL) cholesterol levels in the blood.
SECTION 12.1 Mechanism of Action: reduces total-C and LDL-C (and apo B); SECTION 1.2 Hyperlipidemia indicates reduction of LDL-C.
Lipitor works by inhibiting the production of cholesterol in the liver.
SECTION 12.1: selective, competitive inhibitor of HMG-CoA reductase (mechanistic basis for lipid lowering).
Grapefruit juice contains a compound called furanocoumarin that can interact with Lipitor.
SECTION 7.2 Grapefruit Juice: contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin. (Label text does not name furanocoumarin, but does support a grapefruit-component CYP3A4 interaction.)
Consuming grapefruit juice with Lipitor can increase the risk of side effects.
SECTION 7.2: grapefruit juice can increase plasma concentrations of atorvastatin. (Label does not explicitly state “risk of side effects,” but increased exposure is consistent with increased risk implied by higher concentrations and skeletal muscle risk discussions in SECTION 5.1/DRUG INTERACTIONS.)
Grapefruit juice with Lipitor can lead to increased levels of atorvastatin in the blood.
SECTION 7.2: can increase plasma concentrations of atorvastatin, especially with excessive consumption.
Increased atorvastatin levels in the blood can cause muscle damage and other side effects.
SECTION 5.1 and SECTION 7: increased plasma concentrations with CYP3A4 inhibitors increase risk of myopathy/rhabdomyolysis; grapefruit juice increases plasma concentrations (SECTION 7.2).
Warfarin, digoxin, fibrates, colchicine, cyclosporine, gemfibrozil, and rifampin are some medications that can interact with Lipitor.
Partial. SECTION 7 includes fibrates and cyclosporine and strong CYP3A4 inhibitors; it does not include warfarin, digoxin, colchicine, gemfibrozil (distinct from fibrates), or rifampin in the provided label text.
Fibrates taken with Lipitor can increase the risk of muscle damage.
SECTION 7: risk of myopathy increased with concurrent administration of fibric acid derivatives.
Cyclosporine taken with Lipitor can increase the risk of kidney damage.
Partially supported. SECTION 5.1: rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported; SECTION 7: cyclosporine increases risk of myopathy/rhabdomyolysis. (Label does not explicitly link cyclosporine to “kidney damage” directly, but renal failure is mentioned as consequence of rhabdomyolysis.)
Gemfibrozil taken with Lipitor can increase the risk of muscle damage.
Partially supported. SECTION 7: fibric acid derivatives increase myopathy risk. (Gemfibrozil is a fibric acid derivative, but the label text provided does not explicitly name gemfibrozil.)
Rifampin can decrease the levels of Lipitor in the blood, reducing its effectiveness.
Unsupported (label text provided does not mention rifampin or decreased atorvastatin levels).
The article states it is best to avoid grapefruit juice altogether if you are taking Lipitor.
Partially supported directionally. SECTION 7.2 advises grapefruit juice increases plasma concentrations, especially with excessive consumption (>1.2 L/day), but does not state “avoid grapefruit juice altogether.”
The article states that contacting a doctor immediately is recommended if experiencing side effects such as muscle pain or weakness.
Partially supported. SECTION 5.1: LIPITOR should be temporarily withheld or discontinued in patients with acute, serious condition suggestive of myopathy (example conditions). (Label text provided does not explicitly mention contacting a doctor immediately or “muscle pain or weakness” wording.)
The article states that you should consult your doctor before taking any new medications or consuming grapefruit juice.
Not explicitly supported in the provided label text.
Colchicine taken with Lipitor can increase the risk of muscle damage.
Unsupported. Provided SECTION 7 does not mention colchicine.
Unsupported Statements
Grapefruit juice can lead to decreased levels of the medication in the blood.
SECTION 7.2 provided text states grapefruit juice can increase plasma concentrations of atorvastatin; no label support for decreased levels.
Decreased levels of Lipitor in the blood can reduce its effectiveness.
No label support in provided text for grapefruit juice causing decreased levels; also no provided label statement linking decreased atorvastatin levels (in this context) to reduced effectiveness.
Warfarin taken with Lipitor can increase the risk of bleeding.
Provided SECTION 7 drug interaction text does not mention warfarin or bleeding risk.
Digoxin taken with Lipitor can increase the risk of arrhythmias.
Provided SECTION 7 drug interaction text does not mention digoxin or arrhythmias.
Rifampin can decrease the levels of Lipitor in the blood, reducing its effectiveness.
Provided SECTION 7 drug interaction text does not mention rifampin or direction of effect on atorvastatin levels.
Furanocoumarin
SECTION 7.2 supports grapefruit juice components inhibiting CYP3A4 but does not name “furanocoumarin” in the provided label text.
The article states that you should consult your doctor before taking any new medications or consuming grapefruit juice.
No explicit label language provided for this patient instruction.
The article states that avoiding grapefruit juice is recommended if you are taking Lipitor.
SECTION 7.2 describes increased concentrations especially with excessive grapefruit juice (>1.2 L/day) but does not explicitly recommend avoiding grapefruit juice entirely.
Contradictions
Low
AI Statement
Lipitor with grapefruit juice can lead to decreased levels of the medication in the blood.
Label Reference
SECTION 7.2 Grapefruit Juice: grapefruit juice can increase plasma concentrations of atorvastatin (especially with excessive consumption).
Important Omissions
Label-supported nuance that grapefruit juice effect is especially with excessive consumption (>1.2 liters/day), rather than an across-the-board prohibition.
Importance:
Moderate
Label-supported interaction details for strong CYP3A4 inhibitors (e.g., clarithromycin/itraconazole/HIV protease inhibitors) and dose limits (e.g., cyclosporine limit to 10 mg) are not reflected in the AI claims (beyond cyclosporine general risk).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Some claims align with increased atorvastatin exposure and muscle toxicity risk mechanisms, but several specific interaction outcomes are unsupported (warfarin bleeding, digoxin arrhythmias) and there is at least one contradiction (claim of decreased levels from grapefruit juice). These issues could mislead risk assessment and counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several drug interaction claims are not supported by the provided label text (warfarin, digoxin, colchicine, rifampin) and one grapefruit juice claim contradicts the label direction (decreased vs increased atorvastatin levels).
Suggested Improvement
Restrict interaction statements to those explicitly supported by provided label sections (notably grapefruit juice increases atorvastatin concentrations; fibric acid derivatives and cyclosporine increase myopathy risk; strong CYP3A4 inhibitors increase plasma concentrations). Remove unsupported outcomes (bleeding/arrhythmias) and remove/replace the incorrect statement that grapefruit juice decreases atorvastatin levels. When discussing grapefruit juice, reflect the label’s emphasis on excessive intake (>1.2 L/day) rather than stating avoidance altogether.